Clinical Study

Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study

Abstract

Background

There is no consensus on the effect of sorafenib dosing on efficacy and toxicity in elderly patients with hepatocellular carcinoma (HCC). Older patients are often empirically started on low-dose therapy with the aim to avoid toxicities while maximising clinical efficacy. We aimed to verify whether age impacts on overall survival (OS) and whether a reduced starting dose impacts on OS or toxicity experienced by the elderly.

Methods

In an international, multicentre cohort study, outcomes for those aged <75 or ≥75 years were determined while accounting for common prognostic factors and demographic characteristics in univariable and multivariable models.

Results

Five thousand five hundred and ninety-eight patients were recruited; 792 (14.1%) were aged ≥75 years. The elderly were more likely to have larger tumours (>7 cm) (39 vs 33%, p < 0.01) with preserved liver function (67 vs 57.7%) (p < 0.01). No difference in the median OS of those aged ≥75 years and <75 was noted (7.3 months vs 7.2 months; HR 1.00 (95% CI 0.93–1.08), p = 0.97). There was no relationship between starting dose of sorafenib 800 mg vs 400 mg/200 mg and OS between those <75 and ≥75 years. The elderly experienced a similar overall incidence of grade 2–4 sorafenib-related toxicity compared to <75 years (63.5 vs 56.7%, p = 0.11). However, the elderly were more likely to discontinue sorafenib due to toxicity (27.0 vs 21.6%, p < 0.01). This did not vary between different starting doses of sorafenib.

Conclusions

Clinical outcomes in the elderly is equivalent to patients aged <75 years, independent of dose of sorafenib prescribed.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Kaplan–Meier estimates of overall survival according to age.
Fig. 2: Kaplan–Meier estimates of overall survival according to starting dose of sorafenib received.
Fig. 3: Pie charts demonstrating the reasons for sorafenib discontinuation.

References

  1. 1.

    Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359–E386 (2015).

    CAS  Article  Google Scholar 

  2. 2.

    Llovet, J. M. Updated treatment approach to hepatocellular carcinoma. J. Gastroenterol. 40, 225–235 (2005).

    Article  Google Scholar 

  3. 3.

    Strumberg, D., Richly, H., Hilger, R. A., Schleucher, N., Korfee, S., Tewes, M. et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. 23, 965–972 (2005).

    CAS  Article  Google Scholar 

  4. 4.

    Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).

    CAS  Article  Google Scholar 

  5. 5.

    Cheng, A. L., Kang, Y. K., Chen, Z., Tsao, C. J., Qin, S., Kim, J. S. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25–34 (2009).

    CAS  Article  Google Scholar 

  6. 6.

    Borzio, M., Dionigi, E., Parisi, G., Raguzzi, I. & Sacco, R. Management of hepatocellular carcinoma in the elderly. World J. Hepatol. 7, 1521–1529 (2015).

    Article  Google Scholar 

  7. 7.

    Bosch, F. X., Ribes, J., Cleries, R. & Diaz, M. Epidemiology of hepatocellular carcinoma. Clin. Liver Dis. 9, 191–211 (2005).

    Article  Google Scholar 

  8. 8.

    Cancer Research UK. Liver cancer incidence statistics. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/liver-cancer/incidence (2018).

  9. 9.

    Germano, D., Tinessa, V., Barletta, E., Cannella, L. & Daniele, B. Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib. Drugs Aging 30, 887–892 (2013).

    CAS  Article  Google Scholar 

  10. 10.

    Ziogas, D. C., Papadatos-Pastos, D., Thillai, K., Korantzis, I., Chowdhury, R., Suddle, A. et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem. Eur. J. Gastroenterol. Hepatol. 29, 48–55 (2017).

    CAS  Article  Google Scholar 

  11. 11.

    Pressiani, T., Boni, C., Rimassa, L., Labianca, R., Fagiuoli, S., Salvagni, S. et al. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. Ann. Oncol. 24, 406–411 (2013).

    CAS  Article  Google Scholar 

  12. 12.

    Bruix, J., Cheng, A. L., Meinhardt, G., Nakajima, K., De Sanctis, Y. & Llovet, J. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J. Hepatol. 67, 999–1008 (2017).

    CAS  Article  Google Scholar 

  13. 13.

    Iavarone, M., Cabibbo, G., Piscaglia, F., Zavaglia, C., Grieco, A., Villa, E. et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 54, 2055–2063 (2011).

    CAS  Article  Google Scholar 

  14. 14.

    Nishikawa, H., Takeda, H., Tsuchiya, K., Joko, K., Ogawa, C., Taniguchi, H. et al. Sorafenib therapy for BCLC stage B/C hepatocellular carcinoma; clinical outcome and safety in aged patients: a multicenter study in Japan. J. Cancer 5, 499–509 (2014).

    CAS  Article  Google Scholar 

  15. 15.

    Edeline, J., Crouzet, L., Le Sourd, S., Larible, C., Brunot, A., Le Roy, F. et al. Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors. Cancer Chemother. Pharmacol. 75, 215–219 (2015).

    CAS  Article  Google Scholar 

  16. 16.

    Williet, N., Clavel, L., Bourmaud, A., Verot, C., Bouarioua, N., Roblin, X. et al. Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma. Dig. Liver Dis. 49, 1043–1049 (2017).

    CAS  Article  Google Scholar 

  17. 17.

    Collier, J. D., Curless, R., Bassendine, M. F. & James, O. F. Clinical features and prognosis of hepatocellular carcinoma in Britain in relation to age. Age Ageing 23, 22–27 (1994).

    CAS  Article  Google Scholar 

  18. 18.

    Cabibbo, G., Maida, M., Camma, C. & Craxi, A. Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age? Expert Rev. Anticancer Ther. 13, 1355–1361 (2013).

    CAS  Article  Google Scholar 

  19. 19.

    Jo, M., Yasui, K., Kirishima, T., Shima, T., Niimi, T., Katayama, T. et al. Efficacy and safety of sorafenib in very elderly patients aged 80 years and older with advanced hepatocellular carcinoma. Hepatol. Res. 44, 1329–1338 (2014).

    CAS  Article  Google Scholar 

  20. 20.

    Morimoto, M., Numata, K., Kondo, M., Hidaka, H., Takada, J., Shibuya, A. et al. Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib. Hepatol. Res. 41, 296–302 (2011).

    CAS  Article  Google Scholar 

  21. 21.

    Cox, D. R. Regression models and life-tables. J. R. Stat. Soc. Ser. B Methodol. 34, 187–220 (1972).

    Google Scholar 

  22. 22.

    White, I. R. & Royston, P. Imputing missing covariate values for the Cox model. Stat. Med. 28, 1982–1998 (2009).

    Article  Google Scholar 

  23. 23.

    Abbasi, J. Older patients (still) left out of cancer clinical trials. JAMA https://doi.org/10.1001/jama.2019.17016 (2019).

  24. 24.

    Brunot, A., Le Sourd, S., Pracht, M. & Edeline, J. Hepatocellular carcinoma in elderly patients: challenges and solutions. J. Hepatocell. Carcinoma 3, 9–18 (2016).

    Article  Google Scholar 

  25. 25.

    Di Costanzo, G. G., Tortora, R., De Luca, M., Galeota Lanza, A., Lampasi, F., Tartaglione, M. T. et al. Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma. Med. Oncol. 30, 446 (2013).

    Article  Google Scholar 

  26. 26.

    Francini, E., Mazzaroppi, S., Fiaschi, A. I., Petrioli, R., Laera, L., Roviello, G. et al. Safety of sorafenib therapy in elderly adults with advanced hepatocellular carcinoma. J. Am. Geriatr. Soc. 62, 2204–2205 (2014).

    Article  Google Scholar 

  27. 27.

    Cantarini, M. C., Trevisani, F., Morselli-Labate, A. M., Rapaccini, G., Farinati, F., Del Poggio, P. et al. Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma. Am. J. Gastroenterol. 101, 91–98 (2006).

    Article  Google Scholar 

  28. 28.

    Hung, A. K. & Guy, J. Hepatocellular carcinoma in the elderly: Meta-analysis and systematic literature review. World J. Gastroenterol. 21, 12197–12210 (2015).

    Article  Google Scholar 

  29. 29.

    Howell, J., Pinato, D. J., Ramaswami, R., Bettinger, D., Arizumi, T., Ferrari, C. et al. On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study. Aliment. Pharmacol. Ther. 45, 1146–1155 (2017).

    CAS  Article  Google Scholar 

  30. 30.

    Reiss, K. A., Yu, S., Mamtani, R., Mehta, R., D’Addeo, K., Wileyto, E. P. et al. Starting dose of sorafenib for the treatment of hepatocellular carcinoma: a retrospective, multi-institutional study. J. Clin. Oncol. 35, 3575–3581 (2017).

    CAS  Article  Google Scholar 

  31. 31.

    Reig, M., Torres, F., Rodriguez-Lope, C., Forner, A., N, L. L., Rimola, J. et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J. Hepatol. 61, 318–324 (2014).

    CAS  Article  Google Scholar 

  32. 32.

    Diaz-Gonzalez, A., Sanduzzi-Zamparelli, M., Sapena, V., Torres, F., N, L. L., Iserte, G. et al. Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib. Aliment. Pharmacol. Ther. 49, 482–491 (2019).

    Article  Google Scholar 

  33. 33.

    Tovoli, F., Ielasi, L., Casadei-Gardini, A., Granito, A., Foschi, F. G., Rovesti, G. et al. Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. J. Hepatol. 71, 1175–1183 (2019).

    CAS  Article  Google Scholar 

  34. 34.

    Rimassa, L., Cicin, I., Blanc, J.-F., Klümpen, H. J., Zagonel, V., Tran, A. et al. Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC). J. Clin. Oncol. 36, 4090–4090 (2018).

    Article  Google Scholar 

  35. 35.

    Moth, E. B., Kiely, B. E., Naganathan, V., Martin, A. & Blinman, P. How do oncologists make decisions about chemotherapy for their older patients with cancer? A survey of Australian oncologists. Supportive Care Cancer 26, 451–460 (2018).

    CAS  Article  Google Scholar 

  36. 36.

    Corre, R., Greillier, L., Le Caer, H., Audigier-Valette, C., Baize, N., Berard, H. et al. Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer: the phase III randomized ESOGIA-GFPC-GECP 08-02 study. J. Clin. Oncol. 34, 1476–1483 (2016).

    CAS  Article  Google Scholar 

  37. 37.

    Decoster, L., Kenis, C., Van Puyvelde, K., Flamaing, J., Conings, G., De Greve, J. et al. The influence of clinical assessment (including age) and geriatric assessment on treatment decisions in older patients with cancer. J. Geriatr. Oncol. 4, 235–241 (2013).

    Article  Google Scholar 

  38. 38.

    Food & Drug Administration & H. H. S. International Conference on Harmonisation; Guidance on E7 Studies in Support of Special Populations; Geriatrics; Questions and Answers; availability. Notice. Fed. Regist. 77, 9948–9949 (2012).

    Google Scholar 

  39. 39.

    National Institutes of Health. Revision: NIH Policy and Guidelines on the Inclusion of Individuals Across the Lifespan as Participants in Research Involving Human Subjects (National Institutes of Health, Bethesda, MD, 2017).

  40. 40.

    McNamara, M. G., Slagter, A. E., Nuttall, C., Frizziero, M., Pihlak, R., Lamarca, A. et al. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis. Eur. J. Cancer 105, 1–9 (2018).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Contributions

R.S., S.H. and E.A. performed all analyses and wrote the manuscript. L.M.A. contributed to the analysis and manuscript. T.A., D.B., M.P., L.R., T.P., N.P., L.G., M.K., R.T., J.-W.P., T.H.T., D.E.K., R.R. and D.J.P. all provided data and clinical input into the study and manuscript. R.S. conceived the study design, supervised the study and provided data and clinical input and mentorship for the study.

Corresponding author

Correspondence to Rohini Sharma.

Ethics declarations

Ethics approval and consent to participate

The study protocol was approved by the Yorkshire & The Humber - Sheffield Research Ethics Committee in the UK (Reference 17/YH/0015), as well as the institutional review boards in each participating institution (Supplementary Information 1). The study was conducted in accordance with the Declaration of Helsinki (update 2004). Subjects provided informed consent in centres with prospective data collection, and in centres with retrospective data collection consent was waived by the respective institutional review boards.

Consent to publish

All authors have read the paper and consent to publication.

Data availability

Data are available from individual institutions.

Competing interests

L.R.: consulting and advisory role: Amgen, ArQule, Basilea, Baxter, Bayer, Celgene, Eisai, Exelixis, Hengrui, Incyte, Ipsen, Italfarmaco, Lilly, MSD, Roche, Sanofi, Sirtex Medical; honoraria and lectures: AbbVie, AstraZeneca, Gilead; travel expenses: ArQule, Ipsen. D.B.: consulting and advisory: Bayer Healthcare, Boston Scientific; honoria and lectures: Falk Foundation. N.P.: consulting and advisory role: Amgen, Merck Serono, Servier; lectures: AbbVie, Gilead, Lilly; travel expenses: Amgen, ArQule. D.J.P.: research funding: MSD, Bristol-Myers Squibb, Franco Trevisani; consulting and advisory role: Bayer AG, Alfasigma, Bristol-Myers Squibb; lectures: Bayer AG, Roche, Falk Foundation; travel, accommodations, expenses: Bayer AG. R.S.: research funding: Incyte, AAA; consulting and advisory role: Esai, Roche, Bayer AG, SIRTEX; lectures: Bayer AG, Falk Foundation. No other author has any conflict of interest to declare.

Funding information

No funding was received for this study.

Additional information

Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hajiev, S., Allara, E., Motedayеn-Aval, L. et al. Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study. Br J Cancer (2020). https://doi.org/10.1038/s41416-020-01116-9

Download citation

Search